SCHEMBL26313

SCHEMBL26313

CCCOC(=O)CN(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.46
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
NAAA Q02083 1/20 0.40
DGKA P23743 1/20 0.40
ALDH1A1 P00352 5/20 0.39
HCAR2 Q8TDS4 1/20 0.39
CHRM1 P11229 3/20 0.37
CHRM2 P08172 2/20 0.37
CHRM4 P08173 2/20 0.37
CHRM5 P08912 2/20 0.37
CHRNB2 P17787 2/20 0.37
CHRM3 P20309 2/20 0.37
CHRNA4 P43681 2/20 0.37
LMNA P02545 1/20 0.36
ESR1 P03372 1/20 0.35
TSHR P16473 1/20 0.35
SLC6A2 P23975 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2143046 0.86 ALDH1A1 (0.52) DNM1NAAADGKAALDH1A1HCAR2
SCHEMBL25917458 0.86 DNM1 (0.41) DNM1CA12CA1CA2CA9
SCHEMBL8377133 0.85 NAAA (0.61) DNM1NAAADGKAALDH1A1HCAR2
SCHEMBL8374691 0.83 NAAA (0.64) DNM1NAAADGKAALDH1A1HCAR2
SCHEMBL1671755 0.83 NAAA (0.64) DNM1NAAADGKAALDH1A1HCAR2
SCHEMBL31136183 0.83 NAAA (0.64) DNM1NAAADGKAALDH1A1HCAR2
SCHEMBL2854828 0.83 NAAA (0.64) DNM1NAAADGKAALDH1A1HCAR2
SCHEMBL6667798 0.83 NAAA (0.64) DNM1NAAADGKAALDH1A1HCAR2
SCHEMBL465967 0.83 NAAA (0.64) DNM1NAAADGKAALDH1A1HCAR2
SCHEMBL1672723 0.83 NAAA (0.64) DNM1NAAADGKAALDH1A1HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250235559-A1 GENE EDITING REPORTER SYSTEM AND GUIDE RNA AND COMPOSITION RELATED THERETO; COMPOSITION AND METHOD FOR KNOCKING OUT DNA WITH MORE THAN TWO GRNAS; GENE EDITING IN THE EYE; AND GENE EDITING USING BASE EDITORS Incisive Genetics Inc. (CA) 2025-07-24 US claimed
EP-4577658-A1 COMPOSITIONS AND METHODS FOR PREVENTING, AMELIORATING, OR TREATING SICKLE CELL DISEASE AND COMPOSITIONS AND METHODS FOR DISRUPTING GENES AND GENE SEGMENTS INCISIVE GENETICS, INC. (CA) 2025-07-02 EP claimed
EP-4463555-A1 GENE EDITING REPORTER SYSTEM AND GUIDE RNA AND COMPOSITION RELATED THERETO; COMPOSITION AND METHOD FOR KNOCKING OUT DNA WITH MORE THAN TWO GRNAS; GENE EDITING IN THE EYE; AND GENE EDITING USING BASE EDITORS INCISIVE GENETICS, INC. (CA) 2024-11-20 EP claimed
US-20240358652-A1 LIPID NANOPARTICLE FORMULATIONS MONASH UNIVERSITY (AU) 2024-10-31 US claimed
US-20240293300-A1 SKIN PENETRATION COSMETIC MATERIAL, AND SKIN PENETRATION COSMETIC MATERIAL PRODUCTION METHOD SHISEIDO COMPANY, LTD. (JP) 2024-09-05 US claimed
EP-4409004-A1 COMPOSITIONS AND METHODS FOR PREVENTING, AMELIORATING, OR TREATING SICKLE CELL DISEASE The University of British Columbia (CA) 2024-08-07 EP claimed
EP-4387657-A1 LIPID NANOPARTICLE FORMULATIONS Monash University (AU) 2024-06-26 EP claimed
US-20240175024-A1 DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES ALNYLAM PHARMACEUTICALS, INC. 2024-05-30 US claimed
US-20240175012-A1 GUIDE RNAS AND COMPOSITIONS FOR EDITING HUNTINGTIN GENE, AND METHODS RELATED THERETO UNIV BRITISH COLUMBIA (CA) 2024-05-30 US claimed
WO-2024095213-A1 COMPOSITIONS AND METHODS FOR PREVENTING, AMELIORATING, OR TREATING SICKLE CELL DISEASE AND COMPOSITIONS AND METHODS FOR DISRUPTING GENES AND GENE SEGMENTS INCISIVE GENETICS, INC. (CA) 2024-05-10 WO claimed
US-11827883-B2 Dosages and methods for delivering lipid formulated nucleic acid molecules ALNYLAM PHARMACEUTICALS, INC. (US) 2023-11-28 US claimed
WO-2023161873-A1 GENE EDITING REPORTER SYSTEM AND GUIDE RNA AND COMPOSITION RELATED THERETO; COMPOSITION AND METHOD FOR KNOCKING OUT DNA WITH MORE THAN TWO GRNAS; GENE EDITING IN THE EYE; AND GENE EDITING USING BASE EDITORS INCISIVE GENETICS, INC. (CA) 2023-08-31 WO claimed
WO-2023079465-A1 COMPOSITIONS AND METHODS FOR PREVENTING, AMELIORATING, OR TREATING SICKLE CELL DISEASE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2023-05-11 WO claimed
WO-2023019310-A1 LIPID NANOPARTICLE FORMULATIONS MONASH UNIVERSITY (AU) 2023-02-23 WO claimed
WO-2022195553-A1 GUIDE RNAS AND COMPOSITIONS FOR EDITING HUNTINGTIN GENE, AND METHODS RELATED THERETO THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2022-09-22 WO claimed
WO-2022115739-A1 2022-06-02 WO claimed
EP-3368089-A1 NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES TRANSLATE BIO MA, INC. (US) 2018-09-05 EP claimed
WO-2017075038-A1 NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES RANA THERAPEUTICS, INC. (US) 2017-05-04 WO claimed
CN-101205442-A Ruthenium-barrier layer polishing slurry ROHM & HAAS ELECT MAT (US) 2008-06-25 CN claimed
US-6582687-B1 Skin cleanser containing an alkali salt of N- acylamino acid and maltitolhydroxy aliphatic ether, or a hydroxy ether carboxylic acid-based anionic surfactant, or polyethylene powder, as well as water and an organic acid. Also, SHISEIDO COMPANY, LTD. (JP) 2003-06-24 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240358652-A1 LIPID NANOPARTICLE FORMULATIONS LIPA, LIPC, PHOSPHO1 DNM1 1107/4885CA12 1796/4885CA1 2870/4885
US-20240293300-A1 SKIN PENETRATION COSMETIC MATERIAL, AND SKIN PENETRATION COSMETIC MATERIAL PRODUCTION METHOD CUTA, SLC6A12, DSG1 DNM1 3936/4885CA12 2028/4885CA1 4323/4885
US-20240175024-A1 DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES POLM, POLRMT, ADAR DNM1 1042/4885CA12 4439/4885CA1 4840/4885
US-20250235559-A1 GENE EDITING REPORTER SYSTEM AND GUIDE RNA AND COMPOSITION RELATED THERETO; COMPOSITION AND METHOD FOR KNOCKING OUT DNA WITH MORE THAN TWO GRNAS; GENE EDITING IN THE EYE; AND GENE EDITING USING BASE EDITORS RBM26, RNASEL, MRTO4 DNM1 2419/4885CA12 4771/4885CA1 4789/4885
US-11827883-B2 Dosages and methods for delivering lipid formulated nucleic acid molecules POLM, POLRMT, ADAR DNM1 1042/4885CA12 4439/4885CA1 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.